TIZUREST
Live / Registered — Registered (as of 03 Mar 2026)
What this means for you
Registered since 03 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90302471
- Registration number
- 8155912
- Mark type
- Stylized text
- Filed
- 06 Nov 2020
- Published for opposition
- 13 Dec 2022
- Registered
- 03 Mar 2026
- Attorney of record
- Muzamil Huq
Goods and services
- Class 005 — Pharmaceuticals: Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; human medicines for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; biochemical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medicinal capsules for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical biological preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical ointments, namely, medicated ointments for treating or preventing inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical diagnostic preparations
Owner
- EVIVE BIOTECHNOLOGY (SHANGHAI) LTD., Shanghai, CN
- EVIVE BIOTECHNOLOGY (SHANGHAI) LTD., Shanghai, CN
- EVIVE BIOTECHNOLOGY (SHANGHAI) LTD., SHANGHAI, CN
- Generon (Shanghai) Corporation Ltd., Shanghai, CN
Prosecution history
- 03 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
- 09 Feb 2026 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 06 Feb 2026 — NOTICE OF ALLOWANCE CANCELLED
- 06 Feb 2026 — TEAS DELETE 1(B) BASIS RECEIVED
- 23 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Dec 2025 — SOU EXTENSION 5 GRANTED
- 04 Aug 2025 — SOU EXTENSION 5 FILED
- 22 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Feb 2025 — SOU EXTENSION 4 GRANTED
- 31 Jan 2025 — SOU EXTENSION 4 FILED
- 31 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED